Aurobindo Pharma Ltd - Slight Dip in Profitability Due to Temporary Activities
Quarterly revenue reached Rs. 7,796 crore, reflecting an 8% y-o-y and 3% q-o-q increase, exceeding our estimates by 1%, while PAT was Rs. 817 crore
162 Views
HSIE Results Daily: Shree Cement, Aurobindo Pharma, Gujarat State Petronet
During Q2FY25, Shree volume declined 7% YoY as it focused on trade sales while non-trade demand was weak. Cement NSR fell only 0.4% QoQ, lower vs...
290 Views
Aurobindo Pharma Ltd - Fell Short of Expectations Amidst Mixed Market Performance
Aurobindo Pharma's Q2FY25 results were below expectations, with US revenue of $421 Mn showing minimal growth QoQ , injectable sales experienced a...
223 Views
Axis Top Picks for the Month of November 2024
The Axis Top Picks Basket delivered a return of 11.6% in the last six months against the 7.5% returns posted by Nifty 50 over the same period.
373 Views
Pharma and Healthcare (Q2FY25E Results Preview): Steady Q2, Revlimid to Normalise
The India Pharma & Healthcare sector is expected to maintain its growth momentum in Q2FY25E. We project sales/EBITDA growth of 11%/15% YoY for our...
324 Views